Business Context and Reporting Period
Protalix Biotherapeutics, Inc. (PLX) filed this Form 8-K on August 30, 2019, reporting an event that occurred on August 26, 2019. The Company is incorporated in Delaware and its common stock trades on the NYSE American.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, or debt. However, it discloses the following financial conditions as the basis for regulatory action:
- Stockholders' Equity: Deficiency as of June 30, 2019.
- Net Income: Net losses reported in the five most recent fiscal years ended December 31, 2018.
Material Changes and Listing Status
On August 26, 2019, the Company received a deficiency letter from NYSE American LLC stating non-compliance with continued listing standards under Section 1003(a)(i) – (iii) of the NYSE American Company Guide. This non-compliance is due to the stockholders' equity deficiency and the history of net losses. The letter has no immediate effect on the listing, and the Company's common stock will continue to trade on the NYSE American while it works to regain compliance.
Outlook, Management Commentary, and Risks
Management intends to submit a detailed plan of compliance to the NYSE American within 18 months of receiving the deficiency letter. This plan will outline actions taken or planned to restore compliance with listing standards. The primary risk identified is the potential failure to regain compliance within the specified timeframe, which could lead to delisting.
Investor Verification Checklist
- Verify the specific amount of the stockholders' equity deficiency as of June 30, 2019, in the Company's most recent 10-Q or 10-K.
- Review the detailed compliance plan once submitted to the NYSE American to understand the proposed capital raising or operational strategies.
- Monitor the Company's stock price and trading volume for volatility associated with the deficiency notice.
- Check for any subsequent press releases or filings regarding the status of the compliance plan.